Inactive Instrument
ReNeuron Group plc Stock
Stocks
RENE
GB00BF5G6K95
Biotechnology & Medical Research
OTC Markets Traded
| 24-02-06 | RENEURON ISSUES ADMINISTRATION WARNING | AQ |
| 23-11-27 | Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ | EQ |
| 23-11-16 | ReNeuron : Interim Statement 2023 | PU |
| 23-11-07 | ReNeuron : Presentation | PU |
| 23-07-24 | ReNeuron : 24 July 2023 – Notice of Annual General Meeting | PU |
| 1 day | -2.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2025-03-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Iain Ross
CHM | Chairman | 72 | 2021-06-30 |
| Director/Board Member | 63 | 2021-07-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/12/23 | Buy | Chief Financial Officer | 52,332 | 0.0915% | ||
| 6/16/23 | Buy | Director | 150,000 | 0.2624% | ||
| 6/16/23 | Buy | Chairman | 150,000 | 0.2624% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17% | -11.18% | - | - | 2.58M | |
| -0.72% | +3.41% | +6.32% | +16.27% | 50.03B | |
| -0.76% | +5.86% | +490.20% | +582.89% | 44.36B | |
| +0.07% | +11.56% | +24.37% | +82.30% | 40.82B | |
| +0.97% | +7.22% | +35.87% | +11.30% | 39.83B | |
| +4.73% | +15.53% | +26.95% | +54.62% | 32.51B | |
| -0.58% | +3.95% | - | - | 16.85B | |
| +0.74% | +5.40% | +34.77% | +127.12% | 16.81B | |
| -0.20% | +1.57% | +5.49% | +21.35% | 14.05B | |
| +1.69% | +20.10% | +88.79% | +31.11% | 13.22B | |
| Average | +0.36% | +279.97% | +89.10% | +115.87% | 29.83B | |
| Weighted average by Cap. | +0.53% | +295.32% | +108.08% | +139.51% |
Employees
26
